Background: High-dose therapy followed by autologous stemcell transplantation (autoSCT) induces complete remissions in the majority of patients with advanced B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma (B-CLL). However, the long-term utility of this therapy for B-CLL is unknown.
Introduction
Despite recent progress in the treatment of B-cell chronic lymphocytic leukemia (B-CLL), this disease remains incurable with standard chemotherapy [1] . The average survival after therapy with fludarabine in previously treated patients ranges between nine to 29 months [2] . In view of limited donor availability and the higher transplantation-related toxicity associated with allogeneic hematopoietic stem-cell transplantation, highdose therapy followed by autologous SCT (autoSCT) is an attractive therapeutic option for younger patients with B-CLL. Pilot studies have clearly demonstrated the ability of high-dose therapy and autoSCT to induce complete remissions in the majority of patients with advanced B-CLL [3] [4] [5] [6] [7] [8] [9] [10] [11] . However, the overall clinical experience is limited and follow-up is short, making it difficult to determine the long-term outcome of such therapy for B-CLL. Between 1986 and 1995,16 patients were transplanted at the University of Nebraska Medical Center with autologous stem cells after high-dose therapy for the treatment of B-CLL or small lymphocytic lymphoma [12] . The median age of the patients was 49 years (range 44-60 years), and the patients had a median of two chemotherapy regimens prior to transplantation (Table 1) .
Patients and methods
Eligibility criteria for autoSCT included age less than 60 years, chemosensitive and minimal residual disease (no or minimal organomegaly, lymph nodes less than two centimeter in size, less than 30% bone marrow involvement), no serious organ dysfunction, and a Karnofsky score ^ 80%. Peripheral blood or bone marrow stem cells were used only if there was no morphologic evidence of malignant cells. Patients with leukemic marrow involvement always received peripheral blood stem cells, some patients with negative bone marrow received stem cells as a preference because of faster engraftment potential. These studies were approved by the Institutional Review Board of the University of Nebraska Medical Center and all patients gave informed consent to participate.
Transplantation protocol
High-dose chemotherapy regimens included cyclophosphamide 60 mg/kg/day x 2 days followed by total-body irradiation of 200 cGy twice per day x 3 days (n = 12); BEAC (consisting of carmustine 300 mg/m 2 x 1 day, etoposide 200 mg/m 2 x 4 days, cytarabine 200 mg/m 2 x 4 days, and cyclophosphamide 35 mg/kg x 4 days), (n = 3); or cyclophosphamide and total-body irradiation with the addition of cytarabine (n = 1). Three patients received autologous bone marrow, and 13 patients received autologous peripheral blood stem cells [13] . Abbreviations: C-B -(CAP-BOP) cyclophosphamide, doxorubicin, procarbazine, bleomycin, vincristine, prednisone; DHAP -dexamethasone, cytarabine, cisplatinum, CHOP -cyclophosphamide, doxorubicin, vincristine, prednisone; M-B -(M-BACOD) methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone; P-Cy -(ProMACE-CytaBOM) cyclophosphamide, doxorubicin, etoposide, prednisone, cytarabine, bleomycin, vincristine, methotrexate; FLUD -fludarabine; CNOP -cyclophosphamide, mitoxantrone, vincristine, prednisone; M-B -(MACOP-B) methotexate, doxorubicin, cyclophosphamide, vincristine, bleomycin, prednisone; C-B -(COP-BLAM) cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, procarbazine; MINE -mesna, ifosfamide, mitoxantrone, etoposide; CyEP -cyclophosphamide, etoposide, prednisone; CVP -cyclophosphamide, vincristine, prednisone; CMOPP -cyclophosphamide, mechlorethamine, vincristine, procarbazine, prednisone; ProMACE -prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide; NED -no evidence of disease.
Evaluation and definitions
Before admission for transplant, clinical evaluation included physical examination, a complete blood count, chemistry profile, chest and abdominal CT-scans, bone marrow examination, and pathology review of previous bone marrow and lymph node biopsy specimens. Remission status was assessed by pathological and clinical criteria within 100 days posttransplant. Complete remission (CR) was defined as follows: circulating lymphocytes of less than 4000/ul, less than 30% lymphocytes and the absence of morphologically-abnormal lymphocytes in the bone marrow, no lymphadenopathy or hepatosplenomegaly as assessed by clinical examination and and CT scans. Two patients who had benign-appearing small residual lymphoid aggregates in the bone marrow were considered to be in posttransplant CR. Immunological remission was defined as the absence of clonal B-lymphocytes in the bone marrow as assessed by dual fluorescence flow cytometry using antibodies to CD5, CD19, CD20, CD23 and surface immunoglobulin light-chains (Coulter, Miami, FL).
Study design and statistical methods
This is a single cohort retrospective analysis. The primary outcomes were complete remission, survival and relapse. Failure-free survival was defined as the time to the first occurence of disease progression, relapse, or death. All analyzed events were recorded prospectively. Distribution of time-to-event data was estimated using the KaplanMeier method. 
Remission and relapse
All sixteen patients achieved a complete remission posttransplant. All five of the tested patients also achieved an immunological remission (one had small, benignappearing residual lymphoid aggregates in the bone marrow). Eight patients relapsed at a median of 23.5 months (range 2-34 months). Neither of the two patients with small residual bone marrow aggregates has relapsed. Of interest, two of five patients who were in immunological remission developed recurrent disease. The projected three-year cumulative incidence of relapse was estimated at 56% (Figure 1 ).
Survival

Results
Engraftment
The median number of mononuclear cells infused was 7.5 (1.0-14.3) x lO 8 /kg (n = 16), and the median CFUTen patients are alive at a median of 41 months (range 22-125 months) after transplantation. Five patients are alive and disease-free at a median of 37 months (range 22-125 months), whereas five are alive with relapsed disease at five to 34 months after transplantation (Table 1) . Six patients died at a median of 13.5 months (range 1-39 months), three from disease progression. There was one early death in a patient who developed acute respiratory distress syndrome within the first month posttransplant. One patient died of cerebral hemorrhage at four months, and one died due to secondary marrow failure more than three years after transplantation. The projected three-year overall survival and failurefree survival were 68% and 37%, respectively (Figure 1) .
Discussion
Despite the advent of more effective chemotherapy for B-CLL, patents who fail first-line regimens have a median survival of less than four years [2, 14] , Decrease in the procedure-related mortality over recent years made the autoSCT an appealing therapeutic option for patients with high-risk B-CLL [15] . Several pilot studies have confirmed the potential of high-dose therapy and autoSCT to induce high rates of remission in previously treated B-CLL, some of those remissions were durable at the clinical, immunological and molecular levels [3, 4, 6, 16, 17] . Whether such an approach prolongs diseasefree or overall survival in B-CLL as compared to standard chemotherapy is unclear.
In the current study all B-CLL patients had minimal residual disease at the time of high-dose therapy. Although all patients were in complete remission after transplant, a high rate of relapse was observed and disease progression was the most common cause of death. Of interest, even some patients who achieved an immunological remission experienced relapse. There were three transplantation-related deaths (19%) indicating that autoSCT is still not a toxicity-free procedure.
Investigators from the Dana-Farber Cancer Institute have reported, in a selected group of patients, long-term disease-free survival of 68% after autoBMT for B-CLL using bone marrow purged with an anti-B cell monoclonal antibody cocktail [16, 17] . Many durable remissions were confirmed at the molecular level as assessed by polymerase chain reaction (PCR) amplification of immunoglobulin heavy chain rearrangements, and patients who relapsed remained PCR positive both after purging and posttransplant. These findings suggested that autoSCT with bone marrow purging might have curative potential in B-CLL. In another series of patients, investigators observed a 60% relapse rate after autoBMT for advanced B-CLL in spite of purging the autologous bone marrow with anti-B-cell antibodies [4, 18] . The relapse rate was very similar to those reported herein. Although removing tumor cells from the graft makes an intuitive sense, the role of purging has to await the confirmation in comparative trials with longer follow-up [19] .
High-dose therapy and autoSCT for B-CLL may be more effective when used in patients who are earlier in the course of their disease when drug resistance is less likely to develop [20] . However, current antileukemic regimens may not be sufficient to eradicate B-CLL from the patient, regardless of tumor contamination in the graft, and better antitumor strategies, such as CAMPATH-1H monoclonal antibodies or others, are needed to improve the results of autoSCT [21] .
Allogeneic stem cell transplantation (alloSCT) offers a tumor-free graft and an immunologic graft-versusleukemia effect that appears to be very potent in B-CLL [22, 23] . Preliminary results after matched allogeneic sibling transplantation have demonstrated relapse rates of only 10% and projected survivals between 44% and 57% at three years [3, 8, 24] . However, improvements in safety, such as developement of non-myeloablative preparative regimens, are needed before alloSCT can be routinely offered earlier in the course of disease or to older patients with B-CLL [25] .
The results presented here question the utility of autoSCT in B-CLL patients who are beyond their first complete remission, even in cases with chemosensitive disease. Whether using autotransplants earlier, or the development of more effective autoSCT regimens, could improve outcome for B-CLL remains to be determined in comparative trials with a longer follow-up.
